Investors

Press Releases

Overview
Press Releases
Events + Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
News Alerts

Recent Press Releases

Enveric Biosciences Announces Positive Preclinical Data for EV102 Radiodermatitis Drug Candidate

November 18, 2021

Enveric Biosciences Announces Inclusion in AdvisorShares Psychedelics ETF

November 8, 2021

Enveric Biosciences to Participate in Wonderland: Miami Conference

October 26, 2021

Enveric Biosciences to Participate in Upcoming Investor Conferences in October 2021

October 7, 2021

Enveric Biosciences Announces Artificial Intelligence Platform, PsyAI™, Has Identified Viable Drug Candidates from its ‘Psybrary’ of Psychedelic Molecular Compounds

October 5, 2021

Enveric Biosciences to Participate in Upcoming Investor Conferences in September 2021

September 20, 2021

Enveric Biosciences Announces Closing of MagicMed Industries Acquisition

September 17, 2021

Enveric Biosciences Announces MagicMed Industries’ Presentations at the Following Investor Conferences in September

September 9, 2021

Enveric Biosciences CEO, David Johnson, Issues Letter to Shareholders

August 18, 2021

Enveric Biosciences Announces Approval from Israel’s Ministry of Health to Begin its Phase 1/2 Trial of Triple-Combination CBD Treatment for Glioblastoma

July 8, 2021

Enveric Biosciences and MagicMed to Participate in June 2021 Investor and Industry Conferences

June 3, 2021

Enveric Biosciences Announces Definitive Agreement to Acquire MagicMed Industries, a Pharmaceutical Drug Discovery and Development Platform Focused on New-Generation Psychedelic Molecular Compounds and Derivatives

May 24, 2021

Enveric Biosciences Reports First Quarter 2021 Financial Results

May 18, 2021

Enveric Biosciences Appoints Dr. Arash Asher to Scientific Advisory Board

May 12, 2021

Enveric Biosciences to Participate in the Planet MicroCap Showcase on April 21st

April 14, 2021

Enveric Biosciences Appoints Carter Ward as Chief Financial Officer

April 12, 2021

Enveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021

April 1, 2021

Enveric Biosciences Appoints Dr. Douglas D. Lind to Company’s Board of Directors

March 18, 2021

Enveric Biosciences to Participate in Upcoming Investor Conferences in March

March 15, 2021

Enveric Biosciences Signs Definitive Agreement to Acquire Exclusive License for Novel Molecules from Diverse Biotech

March 10, 2021

Enveric Biosciences Launches Development Collaboration and Supply Agreement with PureForm Global to Support Cannabinoid Clinical Programs

February 25, 2021

Enveric Biosciences Inc. Announces Closing of $12.8 Million Registered Direct Offering of Common Stock

February 12, 2021

Enveric Biosciences Inc. Announces $12.8 Million Registered Direct Offering

February 9, 2021

Enveric Biosciences Issues Shareholder Letter Providing Strategic Vision for Advancing Novel Prescription Supportive Care Cancer Therapies

January 19, 2021

Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering

January 15, 2021

Enveric Biosciences Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

January 12, 2021

Enveric Biosciences Appoints Dr. Marcus Schabacker to Board of Directors

January 5, 2021

Enveric Newsroom

Sign Up for Updates

© 2021 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.